Frank Rimerman Advisors LLC Grows Holdings in Danaher Co. (NYSE:DHR)

Frank Rimerman Advisors LLC boosted its position in Danaher Co. (NYSE:DHR) by 3.6% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 17,048 shares of the conglomerate’s stock after buying an additional 591 shares during the quarter. Frank Rimerman Advisors LLC’s holdings in Danaher were worth $4,740,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in DHR. First Bank & Trust acquired a new position in shares of Danaher in the third quarter worth about $216,000. Wealth Enhancement Advisory Services LLC increased its holdings in Danaher by 1.0% during the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 198,902 shares of the conglomerate’s stock worth $55,299,000 after purchasing an additional 1,992 shares during the last quarter. PFG Investments LLC increased its holdings in Danaher by 55.4% during the 3rd quarter. PFG Investments LLC now owns 5,496 shares of the conglomerate’s stock worth $1,528,000 after purchasing an additional 1,960 shares during the last quarter. Arkadios Wealth Advisors raised its position in shares of Danaher by 1.8% in the 3rd quarter. Arkadios Wealth Advisors now owns 3,572 shares of the conglomerate’s stock valued at $993,000 after purchasing an additional 64 shares in the last quarter. Finally, Forsta AP Fonden boosted its stake in shares of Danaher by 3.0% during the 3rd quarter. Forsta AP Fonden now owns 162,222 shares of the conglomerate’s stock valued at $45,101,000 after buying an additional 4,700 shares during the last quarter. 79.05% of the stock is owned by hedge funds and other institutional investors.

Danaher Stock Performance

DHR opened at $245.39 on Friday. The company has a current ratio of 1.43, a quick ratio of 1.04 and a debt-to-equity ratio of 0.33. The business’s 50 day moving average is $269.52 and its 200-day moving average is $260.42. The stock has a market cap of $181.76 billion, a PE ratio of 41.59, a price-to-earnings-growth ratio of 4.49 and a beta of 0.83. Danaher Co. has a twelve month low of $182.09 and a twelve month high of $281.70.

Danaher (NYSE:DHR) last announced its quarterly earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.57 by $0.14. The company had revenue of $5.80 billion during the quarter, compared to analyst estimates of $5.59 billion. Danaher had a return on equity of 11.06% and a net margin of 16.94%. The firm’s quarterly revenue was up 3.1% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.02 EPS. On average, analysts predict that Danaher Co. will post 7.59 earnings per share for the current year.

Danaher Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Friday, October 25th. Shareholders of record on Friday, September 27th were paid a dividend of $0.27 per share. The ex-dividend date was Friday, September 27th. This represents a $1.08 annualized dividend and a yield of 0.44%. Danaher’s payout ratio is 18.31%.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on DHR. Stifel Nicolaus upped their price target on shares of Danaher from $250.00 to $265.00 and gave the company a “hold” rating in a report on Wednesday. Bank of America upped their target price on shares of Danaher from $270.00 to $275.00 and gave the company a “neutral” rating in a research note on Wednesday, July 24th. Robert W. Baird decreased their price target on Danaher from $278.00 to $277.00 and set an “outperform” rating for the company in a research note on Wednesday. Evercore ISI upped their price objective on Danaher from $275.00 to $278.00 and gave the company an “outperform” rating in a research note on Tuesday, October 1st. Finally, The Goldman Sachs Group increased their target price on Danaher from $225.00 to $250.00 and gave the stock a “neutral” rating in a report on Wednesday, July 24th. Seven analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $287.28.

Insiders Place Their Bets

In other news, CEO Rainer Blair sold 9,007 shares of the stock in a transaction that occurred on Wednesday, July 31st. The shares were sold at an average price of $280.00, for a total value of $2,521,960.00. Following the completion of the transaction, the chief executive officer now directly owns 97,983 shares in the company, valued at $27,435,240. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In other news, CEO Rainer Blair sold 9,007 shares of the company’s stock in a transaction on Wednesday, July 31st. The stock was sold at an average price of $280.00, for a total value of $2,521,960.00. Following the completion of the sale, the chief executive officer now owns 97,983 shares in the company, valued at $27,435,240. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, SVP Georgeann Couchara sold 952 shares of Danaher stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $268.37, for a total value of $255,488.24. Following the transaction, the senior vice president now directly owns 4,212 shares in the company, valued at approximately $1,130,374.44. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 30,059 shares of company stock worth $8,400,897. 11.10% of the stock is owned by corporate insiders.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.